Redeye views the recently announced progress on US reimbursements positively, as a second payor has ...
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the...
NoHo Partners will publish its Q2 2025 results on 5 August, at around 8:00 EET.
Redeye provides a comment on DalaVind’s divestment of Fageråsen, an onshore wind project of more tha...
Vaisala’s Q2 fell short of our estimates due to weaker than expected performance in W&E.
Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and great...
Redeye states that Gapwaves delivered a solid report with beats across key metrics.
Soft Q2, but heading in the right direction We forecast Q2 sales of EUR 27.
W&E headwinds had a greater impact than we anticipated in Q2, resulting in net sales coming in sligh...
Redeye updates its estimates and valuation following Eniro's Q2 2025 report and a change of lead ana...
Stronger order intake, but lower sales Cavotec reported order intake of EUR 44m (+7% vs.
Redeye notes that Gapwaves' Q2 2025 report exceeded its estimates on all key metrics.
Redeye is happy to see OXE Marine beating our forecasts across the board.
Redeye comments on Polygiene Group´s Q2 2025. Polygiene Group delivered negative growth of -12% y/y.
Sales and EBIT miss of SEK 22m and 7m vs. ABGSCe This afternoon, Energy Save issued a profit warning...
